MEDITWIN

IHU PRISM is the national center for precision medicine in oncology, based at Gustave Roussy (Villejuif, France). It aims to improve cancer treatment by modeling each patient's disease using molecular profiling, computational oncology, AI-driven analysis, and advanced biotechnologies. Its translational and clinical research programs validate innovative diagnostics and therapies, redefining the classification and treatment of cancers to improve survival and reduce treatment toxicity.

IHU PRISM was founded by Gustave Roussy, Paris-Saclay University, CentraleSupélec, Unicancer, and Inserm.

Fabrice André, CEO of IHU PRISM at Gustave Roussy
"The MEDITWIN consortium is in line with PRISM's vision of developing cancer avatars to model biology at the patient level and tailor personalized therapies. PRISM will also benefit from the expertise of the other IHUs, and will be working closely with them to develop interdisciplinary projects."

Institut Imagine is a center dedicated to genetic diseases, with the ambition of transforming the lives of the families affected.  This public-private center brings together researchers, doctors, and patients, with a common goal: to cure genetic diseases.  Our four missions: understand the mechanism of diseases; invent the therapies and treatments of tomorrow; capitalize on the results of research; share knowledge through education and training.

Prof. Stanislas Lyonnet, CEO of Institut Imagine
"Institut Imagine is proud to have been one of the initiators of the strategic partnership between Dassault Systèmes and Alliance IHU France on virtual twins. We are delighted to put our medical and research excellence in the field of rare diseases at the service of the MEDITWIN project."

The Foundation for Innovation in Cardiometabolism and Nutrition (IHU ICAN) is a center of excellence in translational research on metabolic diseases: diabetes, obesity, metabolic liver disease (MASH/NASH), and heart and vascular diseases. Established in 2011, IHU ICAN is located in the heart of the Pitié Salpêtrière Hospital and draws on the expertise of its founding members (Assistance Publique Hôpitaux de Paris (AP-HP), the French National Institute of Health and Medical Research (Inserm) and Sorbonne University (SU)) to carry out its mission. IHU ICAN has developed cutting-edge platforms for translational research, particularly for cardio-metabolic tissue imaging, as well as for the integration of clinical and multi-omic data, and for conducting studies incorporating artificial intelligence. Our mission is to accelerate the application of preclinical and clinical research results directly to the care of patients suffering from metabolic diseases.

Prof. Stéphane Hatem, CEO of IHU ICAN 
"Virtual twin technology opens up possibilities for novel precision and preventive medicine for cardiometabolic diseases. Its goal is to predict the personal future risk of developing a cardiovascular disease, based on individual risk profiles, especially the genomic signature. Such an ambition requires changing the scale of today’s research that will be achieved through the MEDITWIN project led by Dassault Systèmes and with all its partners on board."

IHU FOReSIGHT for Vision aims to shape the future of ophthalmology care by accelerating research and access to therapeutic innovations. Founded by the 15-20 National Hospital, Inserm and Sorbonne University, the IHM brings together a truly integrated research and care hub, with the Institut de la Vision, AP-HP, the A. de Rothschild Foundation, and CEA. The IHU develops innovative diagnostic and therapeutic approaches, accelerates their transfer to patients, and develops training programs for scientific and healthcare teams. The Clinical Investigation Center at the 15-20 National Hospital has notably developed advances that enable the analysis of retinal circulation on a micrometric scale.

Prof. Michel Paques, IHU FOReSIGHT, Head of the Ophthalmology 4 Department and Director of the Vision Clinical Investigation Center at the 15-20 National Hospital
"The integration of IHU FOReSIGHT into the MEDITWIN consortium will enable the large-scale development of retinal microcirculation twins, enabling personalized detection and monitoring of cerebral and cardiovascular diseases in quantitative terms. This approach, unique in the world, will be strengthened with Dassault Systèmes through the development of AI to extract morphometric information from large retinal surfaces."

Paris Brain Institute is a scientific and medical research center dedicated to the study of the brain and the discovery of new treatments for diseases of the nervous system. Its innovative model brings together patients, doctors, researchers, and entrepreneurs, in Paris at the heart of the Pitié-Salpêtrière Hospital. The Institute has more than 1,000 international experts in 29 research teams, 12 cutting-edge technology platforms, a clinical investigation center, a training organization, and an innovation hub including a startup studio and a living lab. It is based on the association of a joint research unit (CNRS, Inserm, and Sorbonne University) and a private foundation recognized as being of public utility, the ICM Foundation, in partnership with AP-HP.

Prof. Stéphanie Debette, CEO of Paris Brain Institute, IHU ICM
"The digital twin embodies the ambitions of the Institute's research: to streamline the use of health data at different scales, to model and predict the evolution of diseases, to diagnose early, and to build personalized medicine on a solid and reliable foundation." 

Inria is France’s national research institute for digital science and technology. It is responsible for the Digital Program Agency, which aims to strengthen collective dynamics in higher education and research. World-class research, technological innovation, and entrepreneurial risk-taking are in its DNA. Within 220 project teams, most of which are shared with major research universities, more than 3,800 scientists explore new avenues, often in an interdisciplinary manner and in collaboration with industrial partners to meet ambitious challenges. As a technology institute, Inria supports the diversity of innovation pathways, from open source software publishing to the creation of technological startups (Deeptech). Inria has been awarded the Carnot Institute label, confirming its commitment to bringing research and industry closer together.

Bruno Sportisse, CEO of Inria
"In line with their strategic partnership signed in 2021, Inria and Dassault Systèmes are actively collaborating in the field of virtual twins in healthcare, with an aligned vision of the challenges of sovereignty and the digital transformation of healthcare. Supported by France 2030, the MEDITWIN project, resulting from ambitious collaboration between Dassault Systèmes, Inria and IHU France, demonstrates the commitment of these players to building a French industry at the forefront of emerging healthcare issues, all for the benefit of patients." 

codoc is a healthtech company specializing in the development of business applications and the deployment of health data warehouses. codoc supports healthcare and research stakeholders in the reuse of healthcare data to accelerate research and improve patient care management. Founded in 2017, codoc's solutions have proven their worth and are now deployed in around fifteen French hospitals and cited in over a hundred scientific publications.

Arthur Delapalme, Co-founder and CEO of codoc
"The MEDITWIN project has succeeded in bringing together the medical expertise of several different University Hospital Institutes (IHUs). In our view, this multidisciplinary approach is a fruitful way of accelerating research and rapidly bringing the benefits of innovations to patients. As codoc, we are very proud to build one of the seven virtual twins of this project."

inHEART is a deeptech startup specializing in healthcare, based in France and the United States. The company develops online-accessible SaaS solutions for cardiologists, powered by artificial intelligence. inHEART uses cardiac images and electrocardiograms provided by doctors to create a digital twin of the patient's heart, aimed at supporting the treatment of cardiac arrhythmias and the prevention and detection of cardiovascular diseases. The company has robust clinical data and has obtained Class II CE marking, as well as FDA 510(k) clearance. inHEART began marketing its SaaS solution in 2022 and is experiencing rapid growth in its user base in Europe and the United States, with a presence in more than 200 hospitals. 

Todor Jeliaskov, CEO of inHEART
"At inHEART, we are excited to be part of MEDITWIN and on the forefront of the digital health transformation. Within MEDITWIN, inHEART will focus on the prevention of Sudden Cardiac Death, which takes more than 800,000 lives each year. We need to move our healthcare systems from reacting to acute complications to preventing complications. Digital technologies and Artificial Intelligence are accelerating this process." 

Qairnel is a French deeptech startup from Paris Brain Institute, specializing in the development of medical decision support tools for neurodegenerative diseases. It designs predictive models based on artificial intelligence, using heterogeneous data such as cognitive tests, brain imaging, and biomarkers. These tools aim to anticipate the progression of diseases, support early diagnosis, and guide therapeutic choices in a personalized medicine approach. Qairnel works closely with hospitals and research laboratories and has already collaborated with several major players in the pharmaceutical industry in the development of innovative approaches.

Stanley Durrleman, CEO of QAIRNEL
"At Qairnel, we're proud to be part of the MEDITWIN project. Our virtual twins simulate the evolution of a patient in the early stages of Alzheimer's disease. The project will enable us to put these technologies into the hands of practitioners, to propose personalized management schemes and therapeutic strategies. This will enable us to respond to one of the major public health challenges of the 21st century."

Liryc, the Institute for Heart Rhythm Disorders, is a world-renowned multidisciplinary research center dedicated to understanding cardiac arrhythmias and heart function. This institute brings together expertise in several key areas for the MEDITWIN project, including medical imaging, data analysis and AI-based methodologies, signal processing, and cardiac modeling.

Dr. Mélèze Hocini, Acting CEO of IHU Liryc
"With MEDITWIN, we are taking a decisive step forward in high-precision predictive medicine. For LIRYC, this is both an opportunity and a responsibility: that of transforming innovation into concrete solutions to better prevent and treat electrical heart diseases. We’re proud to contribute to this collective ambition and to promote French excellence around the world."

Founded in 2024, Neurometers is a spin-off of Paris Brain Institute dedicated to the development of tools and biomarkers for measuring consciousness. This technology is based on academic research and is already being used in some hospital departments to measure the consciousness of patients in a coma.

Lionel Naccache, Co-Founder of Neurometers
"Neurometers aims to generalize the medical use of the electroencephalogram (EEG) to quantify the cerebral signatures of consciousness and cognition. Our participation in the MEDITWIN project is aimed at improving the quality of our algorithms by analyzing a large cohort of patient EEG recordings in a scalable manner." 

IHU Strasbourg is a translational research institute that combines clinical expertise, biomedical engineering, and innovative technologies such as artificial intelligence, robotics, and digital twins. As the first public institute in France to comply with Good Laboratory Practice (GLP) for the preclinical evaluation of medical devices, it plays a leading role in the development and testing of next-generation medical solutions. Its activities cover preclinical trials, clinical studies (in conjunction with the Strasbourg University Hospitals), health data structuring for AI, and quality and regulatory affairs. IHU Strasbourg is also a leading training center for future researchers, engineers, and clinicians. Thanks to this integrated approach, IHU Strasbourg has established itself as a key player in image-guided surgery and innovative medical devices.

Prof. Christian Debry, CEO, IHU Strasbourg
"Combining modeling and simulation, digital twins are set to revolutionize the healthcare system, especially as advances in data science and AI accelerate R&D in the field by bringing together scientific and medical expertise. Led by an internationally renowned industrial partner, MediTwin is an exceptional project in terms of its ambition and the challenges to be met. It is also the first project to bring together seven university hospital institutes on a single project, uniting a multidisciplinary biomedical research capability that has no parallel anywhere in the world."

Located in the heart of the Nantes Metropolitan Area, Nantes University Hospital has nearly 13,000 employees who contribute to promoting the values of public hospital service: equality, continuity, neutrality, and adaptability. With its nine facilities, Nantes University Hospital is a center of excellence, referral, and reference at both the regional and interregional levels, while providing routine and local healthcare to the 800,000 inhabitants of the Nantes/Saint-Nazaire Metropolitan Area. Located on the south bank of the Loire River, a new hospital will open in 2027. It will serve as the foundation of the future health district, a project of European scale.

Prof. Bertrand Cariou, Director of l’Institut du Thorax, Nantes University Hospital
"Nantes University Hospital, via l’Institut du Thorax, in collaboration with Dassault Systèmes engineers, will carry out developments aimed at improving the prediction of cardiovascular events, which represent the leading cause of death in industrialized countries. To achieve this goal, a pilot study in a very high-risk cardiovascular population will combine clinical, multi-omics and imaging data to create a virtual twin model, which will then be validated in a larger cardiovascular population." 

Dassault Systèmes is an accelerator of human progress. Since 1981, the company has been creating virtual worlds to serve real life, with the aim of improving the lives of consumers, patients, and citizens. Through Dassault Systèmes' 3DEXPERIENCE platform, 370,000 customers of all sizes and from all sectors can collaborate, imagine, and design sustainable innovations that have a meaningful impact.  

Bernard Charlès, Chairman of the Board of Directors of Dassault Systèmes
"Virtual twins have successfully enabled the industrial world to transform itself more sustainably. Today, this technology is opening up new possibilities for healthcare by revealing the secrets of the human body - by understanding and representing the invisible. For 40 years, Dassault Systèmes has been a pioneer in virtual twins, and we can apply our knowledge and know-how to transform medical practice. The MEDITWIN public-private alliance is a major step forward, mobilizing the best of medicine, science, and technology to serve future healthcare."